By Farhad — 21 November 2026
Daraxonrasib is a new once-daily pill for pancreatic cancer that, in a large Phase III trial, doubled median survival — 13.2 months versus 6.6 months on chemotherapy — for people with previously treated metastatic pancreatic cancer. Published in the New England Journal of Medicine in 2026, the trial also cut the risk of death by 60%. It is not a cure, and it is for specific patients only, but researchers call it a major step forward for one of the hardest cancers to treat.
Daraxonrasib targets the RAS signals pancreatic cancer cells depend on.
What Is Daraxonrasib?
Daraxonrasib, sold under the brand name Rasonque, is a targeted cancer medicine taken as a pill. It belongs to a new class of drugs called RAS(ON) inhibitors, designed to block a specific signal pancreatic cancer cells need to grow — unlike chemotherapy, which attacks fast-growing cells throughout the body.
It works by binding to a protein called cyclophilin A, which switches off RAS signalling — the faulty growth signal behind most pancreatic cancers. Around 90% of pancreatic cancers are driven by KRAS gene mutations, and RAS G12 is the most common type. For decades, RAS was considered "undruggable". Daraxonrasib is one of the first drugs to block it in patients.
Interest has surged this week: Google Trends in the US shows searches for "pancreatic cancer drug daraxonrasib" up more than 1,000%, with over 50,000 searches.
The Trial Results: Survival Doubled
The evidence comes from the Phase III RASolute 302 trial, published in the New England Journal of Medicine in 2026. It enrolled 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. At 59 sites in 6 countries, patients were randomly assigned 1:1 to daraxonrasib (300 mg by mouth once daily) or chemotherapy chosen by their doctor.
The headline result was survival. In the RAS G12 population, median overall survival — the point at which half of patients were still alive — was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy (13.2 vs 6.7 months overall). The trial showed the risk of death was reduced by 60%.
Other measures pointed the same way. Median progression-free survival — time before the cancer started growing again — was 7.3 months versus 3.5 months. The objective response rate, the share of patients whose tumours shrank by a meaningful amount, was 33.2% versus 11.8%. The trial was led by Dr Eileen M. O'Reilly (Memorial Sloan Kettering), Dr Zev A. Wainberg (UCLA) and Dr Brian M. Wolpin (Dana-Farber).
Why does this matter? Pancreatic cancer is one of the hardest cancers to treat, and second-line options — treatments used after the first stops working — have changed little in years. Its five-year survival remains among the lowest of common cancers. Doubling median survival here is a genuine advance, though still measured in months, not years.
Daraxonrasib is taken as a pill once a day.
Promising First-Line Combination Results
The trial results above were in patients whose cancer had already been treated. New data presented on 20 November 2026 at the EORTC-NCI-AACR conference in Barcelona looked at daraxonrasib as a first treatment, combined with chemotherapy. In the RMC-GI-102 study, 61 patients who had not yet been treated for metastatic pancreatic cancer received daraxonrasib (200 mg daily) with gemcitabine and nab-paclitaxel.
After a median follow-up of 18.3 months, researchers reported an objective response rate of 60.7% — tumours shrank by a meaningful amount in about six in ten patients. Complete responses, where tumours were no longer detectable, were seen in 8.2% (about one in twelve). The disease control rate was 90.2%, median progression-free survival was 12.8 months, and the 12-month overall survival rate was 76.6%.
These are early results from a smaller study, not a large Phase III trial, so they need confirming. But they explain why doctors are watching this drug: the combination appears to work well when given first. A larger frontline trial, RASolute 303, is now testing daraxonrasib against chemotherapy alone; RASolute 304 is studying it after surgery.
Side Effects: What the Trial Reported
The most common side effects were rash (86.3%), diarrhoea (67.2%) and stomatitis — soreness inside the mouth (54.8%). Most were grade 1 or 2, meaning mild or moderate, and doctors could usually manage them.
Serious side effects were less common with daraxonrasib than with chemotherapy: grade 3 or higher adverse events occurred in 61.8% of patients, versus 69.6% on chemotherapy. But the trial also reported one death from treatment-related pneumonitis, an inflammation of the lungs — a reminder that even a targeted pill needs careful monitoring.
Anyone taking daraxonrasib should report a new rash, persistent diarrhoea, mouth sores or breathing problems to their care team straight away, so the dose can be adjusted or paused if needed.
Ask your oncologist if daraxonrasib fits your situation.
Who Is Daraxonrasib For?
According to OncLive, the FDA has approved daraxonrasib monotherapy for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent therapy. The European Commission has also approved it, and in the US the drug is available through an early access program.
That approval is narrow on purpose. Daraxonrasib is not for every pancreatic cancer patient — it is for people whose cancer has spread, who have already had at least one other treatment, and whose tumours carry the RAS mutations the drug targets. An oncologist can confirm this with genetic testing of the tumour.
And to be clear: daraxonrasib is not a cure. The trial showed it can extend life and slow the cancer for many patients — a real advance — but the cancer still progresses in most people over time. If you or a loved one has pancreatic cancer, talk to your oncologist about whether it fits your situation. Do not start, stop or change any treatment based on news reports alone.
Staying healthy during treatment matters too. See our guide on how to stay healthy in winter 2026, our explainer on how much vitamin D to take in winter, and the best Black Friday fitness tracker deals of 2026.
What Comes Next
RASolute 303 is testing the drug as a first treatment, against chemotherapy alone, and RASolute 304 is studying it after surgery, when the goal is to stop the cancer coming back. If those trials confirm the early results, daraxonrasib could move from a second-line option to a treatment used much earlier.
For now, the message is simple: after decades in which RAS was thought untreatable, a pill that switches it off has doubled survival in a large trial. That is why daraxonrasib is the most searched cancer drug today. Read the trial report in Oncology Times on daraxonrasib doubling survival, the combination results in ecancer's report on the daraxonrasib combination, and the first-line data at OncLive on daraxonrasib plus chemotherapy.
For another story of science being shaken up, read our Riemann hypothesis proof claim — and for a very different comeback, Sylvester Stallone and Rocky. You can also read this post at Daraxonrasib: The New Pancreatic Cancer Pill That Doubled Survival.
Frequently Asked Questions
What is daraxonrasib?
Daraxonrasib, sold under the brand name Rasonque, is a once-daily pill for pancreatic cancer. It is a RAS(ON) inhibitor: it binds to a protein called cyclophilin A and blocks the RAS growth signals that pancreatic cancer cells depend on. Around 90% of pancreatic cancers are driven by KRAS mutations, and RAS G12 is the most common type.
How much did daraxonrasib improve survival in the trial?
In the Phase III RASolute 302 trial, published in the New England Journal of Medicine in 2026, median overall survival was 13.2 months with daraxonrasib compared with 6.6 months with chemotherapy in the RAS G12 population (13.2 vs 6.7 months overall), and the trial showed the risk of death was reduced by 60%. Median progression-free survival was 7.3 months versus 3.5 months, and the objective response rate was 33.2% versus 11.8%.
What are the side effects of daraxonrasib?
The most common side effects reported in the trial were rash (86.3%), diarrhoea (67.2%) and stomatitis, or mouth soreness (54.8%), mostly mild or moderate (grade 1-2). Serious (grade 3 or higher) side effects occurred in 61.8% of patients on daraxonrasib versus 69.6% on chemotherapy. One death from treatment-related pneumonitis, an inflammation of the lungs, was reported.
Who can receive daraxonrasib?
According to OncLive, the FDA has approved daraxonrasib for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent therapy, and the European Commission has also approved it. It is for specific patients with RAS-mutated, previously treated metastatic disease — your oncologist can confirm eligibility with tumour testing.
Is daraxonrasib a cure for pancreatic cancer?
No. Daraxonrasib is not a cure. The trial showed it can extend life and slow the cancer for many patients with previously treated metastatic pancreatic cancer, which is a major advance, but the cancer still progresses in most people over time. Patients should talk to their oncologist about whether it fits their situation, and should not change treatment based on news reports alone.
Explore More
Find more ideas on Best Home Decoration:
- Living Room
- Bedroom
- Bathroom
- Dining Room
- Small Spaces
- Seasonal Decor
- Trending Post
- Technology
- Health
- Money
- Lifestyle
- Nails
- Fashion
What do you think — does news like this give you hope for pancreatic cancer treatment? Tell us in the comments below.
About the author: Farhad writes about home decoration, money and seasonal deals on Best Home Decoration.